Robert W. Baird Increases Immutep (NASDAQ:IMMP) Price Target to $7.00

Immutep (NASDAQ:IMMP - Get Free Report) had its price objective increased by stock analysts at Robert W. Baird from $6.00 to $7.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the biotechnology company's stock. Robert W. Baird's price target would indicate a potential upside of 241.46% from the stock's current price.

Immutep Stock Down 1.9 %

NASDAQ IMMP traded down $0.04 during mid-day trading on Friday, reaching $2.05. 191,699 shares of the stock were exchanged, compared to its average volume of 220,089. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The business's 50 day moving average is $2.11 and its 200-day moving average is $2.33. Immutep has a 1 year low of $1.58 and a 1 year high of $3.34.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Immutep in the second quarter valued at about $26,000. BNP Paribas Financial Markets raised its stake in shares of Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock valued at $82,000 after purchasing an additional 4,700 shares during the period. XY Capital Ltd acquired a new stake in shares of Immutep during the second quarter worth approximately $105,000. Virtu Financial LLC grew its position in shares of Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after acquiring an additional 32,864 shares in the last quarter. Finally, Meridian Wealth Management LLC grew its holdings in shares of Immutep by 4.5% during the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company's stock valued at $881,000 after purchasing an additional 17,250 shares during the last quarter. Institutional investors and hedge funds own 2.32% of the company's stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.